Replies to post #1775 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Isn't Japan one of the countries where ATIII already carries a DIC indication? The implication of course is that Atryn approval would be met with large market uptake up front<

For this reason, it’s reasonable to expect that GTC could cut a deal that brings in some decent milestone revenue from a Japanese approval.